The promotion of data sharing in pharmacoepidemiology

European Journal of Health Law

Volumn 21, Issue 3, 2014, Pages 271-296

  Sethi, Nayha ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

data protection; data reuse; data sharing; health research; pharmacoepidemiology; secondary uses

Indexed keywords

ARTICLE; DRUG SURVEILLANCE PROGRAM; EUROPEAN UNION; HUMAN; INFORMATION DISSEMINATION; INFORMATION PROCESSING; LEGAL ASPECT; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DATA COLLECTION; EUROPEAN UNION; HUMANS; INFORMATION DISSEMINATION; PATIENT SAFETY; PHARMACOEPIDEMIOLOGY;

EID: 84902506551     PISSN: 09290273     EISSN: 15718093     Source Type: Journal    
DOI: 10.1163/15718093-12341323     Document Type: Article

References (119)

1. W. Lowrance, "Learning from experience: privacy and the secondary use of data in health research", Journal of Health Services Research & Policy 8(2) (2003) 2-7.
2. B. Strom, S. Kimmel, S. Hennessy (Eds.), Textbook of Pharmacoepidemiology, second edition, (Chichester: Wiley, 2013) p. 3.
3. Prime Vigilance. 2014. Epidemiology and Pharmacoepidemiology in relation to Pharmacovigilance. Retrieved 16 January 2014, www.primevigilance.com/ information-and-resources/complexities-in-drug-safety/epidemiology-and- pharmacoepidemiology-in-relationto-pharmacovigilance.
4. Medicines and Healthcare products Regulatory Agency. 2013. "Information for healthcare professionals: Adverse drug reactions". Retrieved 7 January 2014, www.mhra.gov.uk.
5. L. Härmark, A. C. van Grootheest, "Pharmacovigilance: methods, recent developments and future perspectives", European Journal of Clinical Pharmacology 64 (2008) 743-752, at 745.
6. Thalidomide was used to treat morning sickness in pregnant mothers and resulted in thousands of babies being born with congenital deformities. W. McBride, "Thalidomide and congenital malformations", Lancet 2 (1961) 1358.
7. These amendments were made to the Food, Drug and Cosmetic Act in 1962. To ensure greater drug safety, drug manufacturers had to prove the efficacy of drugs prior to marketing. J. Greene and S. Podolsky, "Reform, Regulation and Pharmaceuticals - The Kefauver-Harris Amendments at 50", New England Journal of Medicine 367 (2012) 1481-1483.
8. L. Rägo and B. Santoso, "Drug Regulation: History, Present and Future" in: C. van Boxtel, B. Santoso and I. Edwards (eds.), Drug Benefits and Risks: International Textbook of Clinical Pharmacology, revised 2nd edition( IOS Press and Uppsala Monitoring Centre, 2008) 66.
9. Council Directive 65/65/EEC of 26 January 1965 on the approximation of provisions laid down by law, regulation or administrative action relating to medicinal products (OJ L No 22 of 9. 2. 1965, p. 369). (As amended by Directives 66/454/EEC, 75/319/EEC, 83/570/EEC, 87/21/EEC, 89/341/EEC 89/342/EEC 89/343/EEC, 92/27/EEC, 92/73/EEC et 93/39/EEC).
10. With most recent legislative provisions including Directive 2010/84/EU amending, as regards pharmacovigilance, Directive 2001/83/EC and Regulation 1235/2010 amending, as regards pharmacovigilance, Regulation No. 726/2004.
11. See for example: The University of Manchester, "Centre for Pharmacoepidemiology and Drug Safety". Retrieved 26 March 2014, www.pharmacy.manchester.ac.uk/cpds
12. Agencia Española de medicamentos y productos sanitaros (The Spanish Medicines Agency). Retrieved 26 March 2014, www.aemps.gob.es/en/home.htm
13. Agence nationale de sécurité du medicament et des produits de santé. Retrieved 26t March 2014, ansm.sante.fr/Declarerun- effetindesirable/Pharmacovigilance/Organisation-de-la- pharmacovigilancenationale/(offset)/0.
14. At a European level, the European Medicines Agency has established ENCePP (the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance) 'to further strengthen the post-authorisation monitoring of medicinal products in Europe' European Network of Centres for Pharmacoepidemiology and Pharmacivigilance, "What is ENCePP?" 2014. Retrieved 21 January 2014, www.encepp.eu/structure/index.shtml.
15. A. Avery et al., 'Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys' (2011) Technical Report: DOI: 10.3310/hta15200. NIHR HTA, Southampton.
16. See also MHRA Yellow Card Scheme website. Retrieved 25 March 2014, yellowcard.mhra.gov.uk.
17. A. Sun et al., "Unplanned medication discontinuation as a potential pharmacovigilance signal: a nested young person cohort study", BMC Pharmacology and Toxicology 15(11) (2014).
18. Often, ADR detection is carried out through spontaneous reporting, discussed in more detail below, and commonly referred to as pharmacovigilance. Somewhat confusingly, pharmacovigilance and pharmacoepidemiology are sometimes referred to interchangeably.
19. K. Shields and A. Lyerly, "Exclusion of pregnant women from industry-sponsored clinicaltrials", Obstet Gynecol 122(5) (2013) 1077-1081.
20. F. Bourgeois et al., "Pediatric versus adult drug trials for conditions with high pediatric disease burden", Pediatrics 130(2) (2012) 285-292.
21. M. Murdo et al., "Improving recruitment of older people to research through good practice", Age and Ageing 40(6) (2011) 659-665.
22. H. Van Spall et al., "Eligibility Criteria of Randomized Control Trials Published in High-Impact General Medical Journals", Journal of the American Medical Association 297(11) (2007) 1233-1240.
23. A. Heiat, C. Gross and H. Krumholz. "Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials", Archives of Internal Medicine 162(15) (2002) 1682-1688.
24. See for example: S. Schneeweiss et al., "Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study", European Journal of Clinical Pharmacology 58 (2002) 285-291
25. G. Niklas Noren and R. Edwards, "Modern methods of pharmacovigilance: detecting adverse effects of drugs", Clinical Medicine 9(5) (2009) 486-489.
26. A. Jadad and T. Matthew, "Consideration of Multiple Chronic Diseases in Randomized Control Trials", Journal of the American Medical Association 306(24) (2011).
27. T. Ban, "The Role of Serendipity in Drug Discovery", Dialogues Clinical Neuroscience 8(3) (2006) 335-344.
28. T. Ashburn and K. Thor, "Drug repositioning: identifying and developing new uses for existing drugs", National Review of Drug Discovery 3 (2004) 673-683
29. I. Goldstein et al., "Oral Sildenafil in the Treatment of Erectile Dysfunction", New England Journal of Medicine 338 (1998) 1397-1404.
30. B. Knoppers et al., "A human rights approach to an international code of conduct for genomic and clinical data sharing", Human Genet (2014) (epub ahead of print). Retrieved 31 March 2014, www.ncbi.nlm.nih.gov/pubmed/ 24573176.
31. Indicated by the inverted black triangle symbol on the packet.
32. General Medical Council. 2013. "Good practice in prescribing and managing medicines and devices" 31 January 2013. Retrieved 8 April 2014, www.gmc uk.org/guidance/ethical-guidance/14316.asp.
33. The Medicines and Healthcare Products Regulatory Agency Yellow Card Scheme.
34. See MHRA. 2014. "Black Triangle Scheme - new medicines and vaccines subject to EU-wide additional monitoring". Retrieved 28 March 2014, www.mhra.gov.uk/Safetyinformation/Howwemonitorthesafetyofproducts/Medicines/ BlackTriangleproducts/index.htm.
35. L. Hazell and S. Shakir, "Under-Reporting of Adverse Drug Reactions
36. A Systematic Review", Drug Safety 29(5) (2006) 385-396.
37. I. Eland, et al., "Attitudinal survey of voluntary reporting of adverse drug reactions", Journal of Clinical Pharmacology 48(4) (1999) 623-627.
38. D. Williams and J. Feely, "Underreporting of adverse drug reactions: attitudes of Irish doctors", Ir J Med Sci 168(1999) 257-261
39. M. Backstrom et al., "Attitudes to reporting adverse drug reactions in northern Sweden", European Journal of Clinical Pharmacology 56 (2000) 729-732.
40. M. Herdeiro, "Physicians' Attitudes and Adverse Drug Reaction Reporting", Drug Safety 28 (9) (2006) 825-833.
41. M. Bäckström, T. Mjörndal and R. Dahlqvist, "Under-reporting of serious adverse drug reactions in Sweden", Pharmacoepidemiology and Drug Safety 13(7) (2004) 483-487.
42. British Medical Association Board of Science. May 2006. Reporting adverse drug reactions: A guide for healthcare professionals. 2006.
43. P. Arlett and X. Kurz, "New approaches to strengthen pharmacovigilance", Drug Discovery Today: Technologies 8(1) (2011), e15-e19.
44. E. Jackson, Law and the Regulation of Medicines, (Oxford: Hart Publishing, 2012) p. 99.
45. D. Light, "Bearing the Risks of Prescription Drugs" in: D. Light (ed.), The Risks of Prescription Drugs (Columbia University Press, 2010), pp. 1-39, at 7.
46. E. Brook, D. Rosman and C. Holman, "Public good though data linkage: measuring research outputs from the Western Australian Data Linkage System", Australian and New Zealand Journal of Public Health 32(1) (2008) 19-23.
47. I.e. recall bias or interview bias, drop outs and completeness of response may be reduced'. A. Jönsson, "Drug-related morbidity and mortality: Pharmacoepidemiological aspects", Linköping University Medical Dissertations No. 1030, Linköping (2007). Retrieved 23 January 2014, www.diva-portal.org/smash/get/diva2:17207/FULLTEXT01.
48. W. Lowrance, Learning from Experience: Privacy and the Secondary Use of Data in Health Research (2002). (Report) The Nuffield Trust, p 6.
49. P. Coorevits et al., "Electronic health records: new opportunities for clinical research", Journal of Internal Medicine 274 (2013) 547-560.
50. A UK example is the Clinical Practice Research Datalink (CPRD) in the UK This was previously known as the General Practice Research Database. For more information see CPRD website. Retrieved 28 March 2014, www.cprd.com/intro.asp.
51. Pharmo Record Linkage system as developed in the Netherlands. See Pharmo Institute for Outcomes Research. Retrieved 28 March 2014, www.pharmo.nl.
52. Electronic Health Records for Clinical Research (EHR4CR) See EHR4CR website Retrieved 7 April 2014, www.ehr4cr.eu.
53. Medical Research Council. 2012. "E-Health Informatics Research Centres Call." Retrieved 29 August 2012, www.mrc.ac.uk/ Fundingopportunities/Calls/E-healthCentresCall/index.htm.
54. For more information, see The Farr Institute, 2014. Retrieved 9 January 2014, www.farrinstitute.org.
55. G. Laurie and N. Sethi, "Information Governance of Use of Health-Related Data in Medical Research in Scotland: Current Practices and Future Scenarios." (University of Edinburgh School of Law Working Paper No 2011/26, 2011).
56. Academy of Medical Sciences, Personal data for public good: using health information in medical research (2011)
57. Academy of Medical Sciences, A new pathway for the regulation and governance of health research (2012)
58. R. Thomas and T. Walport, Data Sharing Review Report (2008).
59. See for example: European Commission, "Commission Staff Working Paper Impact Assessment" Brussels, 25.01.2012, (SEC2012) 72 final (p. 13)
60. N. Robinson et al., 'Review of the European Data Protection Directive' Technical Report Sponsored by the Information Commissioner's Office, RAND Europe, (2009) ICO
61. Privacy in Research Ethics & Law (PRIVIREAL) Project. Retrieved 7 April 2014, www.privireal.org.
62. M. Witham et al., "Construction of a linked health and social care database resource -lessons on process, content and culture", Informatics for Health and Social Care (2014) (Epub ahead of print). Retrieved 5 April 2014, www.ncbi.nlm.nih.gov/pubmed/24650248.
63. Academy of Medical Sciences, 'Personal data for public good: using health information in medical research' (2006).
64. K. El Emam and L. Arbuckle, Anonymizing Health Data, (USA: O'Reilly Media, 2013), at p. 2.
65. A. Narayanan and V. Schmatikov, 'Myths and fallacies of "Personally Identifiable Information" ', Communications of the ACM 53(6) (2010) 24-26.
66. P. Ohm, "Broken Promises of Privacy: Responding to the Surprising Failure of Anonymization", UCLA Law Review, 57 (2010) 1701.
67. U of Colorado Law Legal Studies Research Paper No. 9-12.
68. S. Fullerton et al., "Meeting the governance challenges of next-generation biorepository research", Science Translational Medicine 2(15) (2010).
69. The Royal Society 2012. 'Science as an Open Enterprise', The Royal Society Science Policy Centre report 02/12.
70. See for example approach in UK Information Commissioner's Office, "Anonymisation: Managing Data Protection Risk: Code of Practice", (2012) p. 12.
71. K. Pommerening and M. Reng, "Secondary use of the EHR via pseudonymisation", Studies in Health Technology and Informatics 103 (2004) 441-446.
72. L. Lo Iacono, "Multi-centric Universal Pseudonymisation for Secondary Use of the HER", Studies in Health Technology and Informatics 126 (2007) 239-247, at p. 239.
73. R. Tinabo et al., "Anonymisation vs. Pseudonymisation: Which one is most Useful for both Privacy Protection and Usefulness of E-healthcare Data?" In Proc. IEEE 4th International Conference for Internet Technology and Secured Transactions (ICITST). (2009) Retrieved 21 January 2014, ieeexplore.ieee.org/xpls/abs-all.jsp?arnumber=5402501&tag=1.
74. House of Commons Health Committee, 'The Electronic Patient Record Sixth Report of Session 2006-07 Volume 1, at p. 91. HC 422-I
75. Iain Bourne, Information Commissioner's Office (ICO) 'The Complexities of Privacy and Anonymity XRDS: Crossroads', The ACM Magazine for Students, Volume 20 Issue 1, Fall 2013 Pages 27-31, ACM New York, NY, USA.
76. UK Information Commissioner's Office, 'Proposed draft EU General Data Protection Regulation and 'law enforcement' Directive. Comparative analysis of the European Commission text and the European Parliament's LIBE (civil liberties) Committee amendments.' Retrieved 7 April 2014, http://ico.org.uk/ news/blog/2013/~/media/documents/library/Data-Protection/Research-and-reports/ Proposed-draft-EU-General-Data-Regulation-and-law-enforcement-Directive- 20140124.pdf.
77. See for example: Journal of American Medical Informatics Association, doi:10.1136/amiajnl-2012-001575.
78. See G. Laurie and N. Sethi, "Towards Principles-Based Approaches to Governance of Health-related Research using Personal Data", European Journal of Risk Regulation 1 (2013) 43-57
79. N. Sethi and G. Laurie, "Delivering proportionate governance in the era of eHealth: Making linkage and privacy work together", Medical Law International 13(2-3) (2013) 168-204.
80. Wellcome Trust. May 2013. 'Impact of the draft European Data Protection Regulation and proposed amendments from the rapporteur of the LIBE committee on scientific research' Retrieved 29 March 2014www.wellcome.ac.uk/stellent/groups/ corporatesite/@policy-communications/documents/web-document/wtvm054713.pdf.
81. European Parliament, 'Q&A on EU data protection reform', 4 March 2014. Retrieved 29 March 2014,www.europarl.europa.eu/pdfs/news/expert/ background/20130502BKG07917/20130502BKG07917-en.pdf.
82. For discussion see: M. Birnhack, "The EU Data Protection Directive: An engine of a global regime", Computer Law & Security Review 24(6) (2008) 508-520
83. P. Schwartz, "European Data Protection Law and Restrictions on International Data Flow", 80 Iowa Law Review 80 (1995) 471.
84. R. Wong, 'The Shape of Things to Come: Swedish Developments on the Protection of Privacy', SCRIPTed 2(1) (2005) 98-113.
85. European Parliament News. 2014. QA on Data Protection Reform, 4 March 2014. Retrieved 17 March 2014, www.europarl.europa.eu/news/en/news-room/content/ 20130502BKG07917/html/QA-on-EU-data-protection-reform.
86. European Commission, Proposal for a Regulation of the European Parliament and of the Council on the protection of individuals with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation), Brussels 25.01.12 COM (2012) 11 final 2012/0011 (COD).
87. Directive 2010/84/EU and Regulation (EU) No 1235/2010 impose obligations on pharmaceutical companies to report adverse events however it has not always been clear how those legislation interact with the EU Data Protection Directive. The Draft Data Protection Regulation specifies that health data may be processed for 'ensuring high standards of quality and safety for medicinal products and product safety' thus potentially providing a clearer legislative base for the use of personal data and the retention of data for research. See: International Pharmaceutical Privacy Consortium. March 2012. 'Comments in response to the call for evidence on EU Data Protection Proposals.' Retrieved 7 April 2014, www.pharmaprivacy.org/download/ IPPC%20Comments%20UK%20Consultation%20on%20Proposed%20Data%20Protection%20Regul ation.pdf.
88. Rapporteur Jan Philipp Albrecht, Committee on Civil Liberties, Justice and Home Affairs, Draft Report on the proposal for a regulation of the European Parliament and of the Council on the protection of individual with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation) COM (2012) 0011 - C7-0025/2012 - 2012/0011(COD)).
89. M. Ploem and K. Stronks, "Proposed EU data protection regulation is a threat to medical research" (Editorial), British Medical Journal 346 (2013)f3534
90. R. Fears et al., "Data protection regulation and the promotion of health research: getting the balance right", Quarterly Journal of Medicine 107 (2014) 3-5.
91. European Parliament, Committee on Civil Liberties, Justice and Home Affairs, 2012/0011(COD), Draft Report on the proposal for a regulation of the European Parliament and of the Council on the protection of individual with regard to the processing of personal data and on the free movement of such data (General Data Protection Regulation) (COM (2012)0011 - C7-0025/2012 - 2012/0011(COD)) Amendment 327 Proposal for a regulation Article 81 - paragraph 2, Hereafter referred to as 'Albrecht Report'.
92. E. Regidor, "The use of personal data from medical records and biological materials: ethical perspectives and the basis for legal restrictions in health research", Social Science and Medicine (54) (2004) 1975-1894, at p. 1976
93. P. Furness and L. Nicholson, "Obtaining Explicit Consent for the Use of Archival Tissue Samples: Practical Issues", Journal of Medical Ethics 20 (2004) 561.
94. G. Laurie, "Evidence of support for biobanking practices", British Medical Journal 337 (2008) 337
95. G. Laurie and E. Postan, "Rhetoric or Reality: What is the legal status of the consent form in health-related research?", Medical Law Review 21(3) (2013) 371-414.
96. M. Andersen and H. Storm, "Cancer registration, public health and the reform of the European data protection framework: Abandoning or improving European public health research?", European Journal of Cancer (2013) (Epub ahead of print).
97. Article 29 Data Protection Working Party, Opinion 05/2014 on Anonymisation Techniques, 0829/14/EN WP216, adopted 10 April 2014.
98. Albrecht Report, Amendment 328, Proposal for a regulation Article 81 - paragraph 2 a (new).
99. Draft Regulation Article 42.
100. Albrecht Report, Amendment 27 Proposal for a regulation Recital 42.
101. M. Gymrek et al., "Identifying personal genomes by surname inference", Science 339 (2013) 321-324.
102. European Commission, Article 29 Working Party. Retrieved 29 March 2014, ec.europa.eu/justice/data-protection/article-29/index-en.htm.
103. Article 29 Data Protection Working Party, Opinion 15/2011 on the definition of consent, Adopted 13 July 2011.
104. Article 29 Data Protection Working Party, Opinion 1/2010 on the concepts of 'controller' and 'processor', 00264/10/EN, WP 169, adopted 16 February 2010.
105. Article 30 Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data.
106. See T. Honderich (ed.), The Oxford Companion to Philosophy (Oxford: Oxford University Press, 1995), p. 719.
107. For more see SHIP website. Retrieved 31 March 2014, www.scot-ship.ac.uk.
108. See scotland.gov.uk/Topics/Statistics/datalinkageframework. Retrieved 7 April 2014.
109. B. Knoppers et al., 'Towards a data sharing Code of Conduct for international genomic research', Genome Medicine 46(3) (2011) 4.
110. L. Sama and V. Shoaf, "Reconciling Rules and Principles: An Ethics-Based Approach to Corporate Governance", Journal of Business Ethics 58 (2005), p. 1
111. See for example, J. Harris, 'In praise of unprincipled ethics', Journal of Medical Ethics 29 (5) (2003) 303-306.
112. See for example: K. Danner Clouser and B. Gert, 'A Critique of Principlism', Journal of Medical Philosophy 15 (1990) 219-236
113. W. Muirhead, 'When four principles are too many: bloodgate, integrity and an action-guiding model of ethical decision making in clinical practice', Journal of Medical Ethics 38 (2012) 195-196.
114. For discussion on rule-based and principle-based regulation, see: A. Kern and N. Moloney, Law Reform and Financial Markets (Cheltenham: Edward Elgar Publishing: 2011) at p. 8
115. J. Black, The Rise, Fall and Fate of Principles Based Regulation (LSE Law Society and Economy Working Papers 17/2010 2010).
116. J. Braithwaite, "Rules and Principles: A Theory of Legal Certainty", Australian Journal of Legal Philosophy 27 (2002).
117. S. Arjoon, "Striking a Balance Between Rules and Principles-based Approaches for Effective Governance: A Risk-based Approach", Journal of Business Ethics 68 (2006) 53 et seq., at p. 65.
118. Regulation (EU) No . . . /2014 of the European Parliament and of the Council on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC.
119. See for example: Journal of the American Medical Informatics Association, doi:10.1136/amiajnl-2012-001575.